MedPath
HSA Product

PHOXILIUM 1.2 MMOL/L PHOSPHATE SOLUTION FOR HAEMODIALYSIS/HAEMOFILTRATION

Product approved by Health Sciences Authority (SG)

Basic Information

PHOXILIUM 1.2 MMOL/L PHOSPHATE SOLUTION FOR HAEMODIALYSIS/HAEMOFILTRATION

SOLUTION, STERILE

Regulatory Information

SIN15730P

June 27, 2019

Prescription Only

Therapeutic

INTRAVENOUS

August 10, 2023

May 30, 2025

XB05ZB

Company Information

BAXTER HEALTHCARE (ASIA) PTE LTD

BAXTER HEALTHCARE (ASIA) PTE LTD

Active Ingredients

Detailed Information

Contraindications

**4.3 Contraindications** Hypersensitivity to the active substance(s) or to any of the excipients listed in section 6.1 – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_. Solution dependent contraindications - Hyperkalaemia - Metabolic alkalosis - Hyperphosphataemia Haemofiltration/- dialysis dependent contraindications - Renal failure with pronounced hypercatabolism, if the uraemic symptoms cannot be corrected with haemofiltration or haemodiafiltration, - Insufficient arterial pressure in the vascular access, - Systemic anticoagulation if there is a high risk of haemorrhage.

Indication Information

**4.1 Therapeutic indications** PHOXILIUM solution is used for CRRT (Continuous Renal Replacement Therapy) in critically ill patients with ARF (Acute Renal Failure) when pH and kalaemia have been restored to normal and when the patients need phosphate supplementation for loss of phosphate in the ultrafiltrate or to the dialysate during CRRT. PHOXILIUM solution may also be used in cases of drug poisoning or intoxications when the poisons are dialyzable or pass through the membrane. PHOXILIUM solution is indicated for use in patients with normal kalaemia and normal or hypophosphataemia.

© Copyright 2025. All Rights Reserved by MedPath